Literature DB >> 32633675

Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?

Lynn Jeanette Savic1, Luzie A Doemel1, Isabel Theresa Schobert1, Ruth Rebecca Montgomery1, Nikhil Joshi1, John James Walsh1, Jessica Santana1, Vasily Pekurovsky1, Xuchen Zhang1, MingDe Lin1, Lucas Adam1, Annemarie Boustani1, James Duncan1, Lin Leng1, Richard John Bucala1, S Nahum Goldberg1, Fahmeed Hyder1, Daniel Coman1, Julius Chapiro1.   

Abstract

Background The immuno-metabolic interplay has gained interest for determining and targeting immunosuppressive tumor micro-environments that remain a barrier to current immuno-oncologic therapies in hepatocellular carcinoma. Purpose To develop molecular MRI tools to reveal resistance mechanisms to immuno-oncologic therapies caused by the immuno-metabolic interplay in a translational liver cancer model. Materials and Methods A total of 21 VX2 liver tumor-bearing New Zealand white rabbits were used between October 2018 and February 2020. Rabbits were divided into three groups. Group A (n = 3) underwent intra-arterial infusion of gadolinium 160 (160Gd)-labeled anti-human leukocyte antigen-DR isotope (HLA-DR) antibodies to detect antigen-presenting immune cells. Group B (n = 3) received rhodamine-conjugated superparamagnetic iron oxide nanoparticles (SPIONs) intravenously to detect macrophages. These six rabbits underwent 3-T MRI, including T1- and T2-weighted imaging, before and 24 hours after contrast material administration. Group C (n = 15) underwent extracellular pH mapping with use of MR spectroscopy. Of those 15 rabbits, six underwent conventional transarterial chemoembolization (TACE), four underwent conventional TACE with extracellular pH-buffering bicarbonate, and five served as untreated controls. MRI signal intensity distribution was validated by using immunohistochemistry staining of HLA-DR and CD11b, Prussian blue iron staining, fluorescence microscopy of rhodamine, and imaging mass cytometry (IMC) of gadolinium. Statistical analysis included Mann-Whitney U and Kruskal-Wallis tests. Results T1-weighted MRI with 160Gd-labeled antibodies revealed localized peritumoral ring enhancement, which corresponded to gadolinium distribution detected with IMC. T2-weighted MRI with SPIONs showed curvilinear signal intensity representing selective peritumoral deposition in macrophages. Extracellular pH-specific MR spectroscopy of untreated liver tumors showed acidosis (mean extracellular pH, 6.78 ± 0.09) compared with liver parenchyma (mean extracellular pH, 7.18 ± 0.03) (P = .008) and peritumoral immune cell exclusion. Normalization of tumor extracellular pH (mean, 6.96 ± 0.05; P = .02) using bicarbonate during TACE increased peri- and intratumoral immune cell infiltration (P = .002). Conclusion MRI in a rabbit liver tumor model was used to visualize resistance mechanisms mediated by the immuno-metabolic interplay that inform susceptibility and response to immuno-oncologic therapies, providing a therapeutic strategy to restore immune permissiveness in liver cancer. © RSNA, 2020 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32633675      PMCID: PMC7434651          DOI: 10.1148/radiol.2020200373

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  35 in total

1.  The Distribution of Inorganic Iron in Plant and Animal Tissues.

Authors:  H W Jones
Journal:  Biochem J       Date:  1920-10       Impact factor: 3.857

Review 2.  Migrating into the Tumor: a Roadmap for T Cells.

Authors:  Lieke L van der Woude; Mark A J Gorris; Altuna Halilovic; Carl G Figdor; I Jolanda M de Vries
Journal:  Trends Cancer       Date:  2017-11-06

3.  Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

Authors:  Shari Pilon-Thomas; Krithika N Kodumudi; Asmaa E El-Kenawi; Shonagh Russell; Amy M Weber; Kimberly Luddy; Mehdi Damaghi; Jonathan W Wojtkowiak; James J Mulé; Arig Ibrahim-Hashim; Robert J Gillies
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

4.  Nanoparticle hydrophobicity dictates immune response.

Authors:  Daniel F Moyano; Meir Goldsmith; David J Solfiell; Dalit Landesman-Milo; Oscar R Miranda; Dan Peer; Vincent M Rotello
Journal:  J Am Chem Soc       Date:  2012-02-24       Impact factor: 15.419

Review 5.  Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.

Authors:  Ping-Chih Ho; Susan M Kaech
Journal:  Curr Opin Immunol       Date:  2017-04-27       Impact factor: 7.486

6.  Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.

Authors:  Julius Chapiro; Surojit Sur; Lynn Jeanette Savic; Shanmugasundaram Ganapathy-Kanniappan; Juvenal Reyes; Rafael Duran; Sivarajan Chettiar Thiruganasambandam; Cassandra Rae Moats; MingDe Lin; Weibo Luo; Phuoc T Tran; Joseph M Herman; Gregg L Semenza; Andrew J Ewald; Bert Vogelstein; Jean-François Geschwind
Journal:  Clin Cancer Res       Date:  2014-10-17       Impact factor: 12.531

7.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

8.  Non-invasive assessment of hepatic iron stores by MRI.

Authors:  Y Gandon; D Olivié; D Guyader; C Aubé; F Oberti; V Sebille; Y Deugnier
Journal:  Lancet       Date:  2004-01-31       Impact factor: 79.321

Review 9.  Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.

Authors:  Riccardo Lencioni; Thierry de Baere; Michael C Soulen; William S Rilling; Jean-Francois H Geschwind
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

10.  Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins.

Authors:  Muneeb Ahmed; Gaurav Kumar; Svetlana Gourevitch; Tatyana Levchenko; Eithan Galun; Vladimir Torchilin; S Nahum Goldberg
Journal:  Int J Hyperthermia       Date:  2018-04-24       Impact factor: 3.914

View more
  9 in total

1.  Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.

Authors:  Antonia M Berz; Jessica G Santana; Simon Iseke; Moritz Gross; Vasily Pekurovsky; Fabian Laage Gaupp; Lynn J Savic; Tabea Borde; Luzie A Gottwald; Anne Marie Boustani; Bernhard Gebauer; MingDe Lin; Xuchen Zhang; Todd Schlachter; David C Madoff; Julius Chapiro
Journal:  J Vasc Interv Radiol       Date:  2022-03-26       Impact factor: 3.682

Review 2.  Probing immune infiltration dynamics in cancer by in vivo imaging.

Authors:  Thomas S C Ng; Harris H Allen; Mohammad Rashidian; Miles A Miller
Journal:  Curr Opin Chem Biol       Date:  2022-02-23       Impact factor: 8.972

3.  Imaging Extracellular Acidification and Immune Activation in Cancer.

Authors:  Fahmeed Hyder; Daniel Coman
Journal:  Curr Opin Biomed Eng       Date:  2021-03-05

4.  Targeting visualization of malignant tumor based on the alteration of DWI signal generated by hTERT promoter-driven AQP1 overexpression.

Authors:  Liang Zhang; Mingfu Gong; Sheng Lei; Chun Cui; Yun Liu; Shilin Xiao; Xun Kang; Tao Sun; Zhongsheng Xu; Chunyu Zhou; Si Zhang; Dong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-19       Impact factor: 10.057

5.  Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model.

Authors:  Federico Collettini; Carolin Reimann; Julia Brangsch; Julius Chapiro; Lynn Jeanette Savic; David C Onthank; Simon P Robinson; Uwe Karst; Rebecca Buchholz; Sarah Keller; Bernd Hamm; S Nahum Goldberg; Marcus R Makowski
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

Review 6.  Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma.

Authors:  Quan Chen; Austin Z Chen; Guorong Jia; Jindian Li; Chuansheng Zheng; Kai Chen
Journal:  Hepatol Commun       Date:  2021-11-05

7.  Early Assessment of Response to Radiofrequency Ablation With CT Perfusion Imaging in Rabbit VX2 Liver Tumor Model.

Authors:  Xiaofei Yue; Xiangjun Dong; Mengting Huang; Hongli Yang; Kun Qian; Changhong Yi; Osamah Alwalid; Yanqiao Ren; Ping Han; Qian Li
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

8.  Hepatoprotective role of peroxisome proliferator-activated receptor-α in non-cancerous hepatic tissues following transcatheter arterial embolization.

Authors:  Peiyu Yang; Zhengliang Li; Wei Du; Chunhua Wu; Wencui Xiong
Journal:  Open Life Sci       Date:  2022-08-11       Impact factor: 1.311

Review 9.  HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.

Authors:  Sandeep Arora; Roberta Catania; Amir Borhani; Natally Horvat; Kathryn Fowler; Carla Harmath
Journal:  Abdom Radiol (NY)       Date:  2021-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.